What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To investigate the safety and feasibility of combining loncastuximab tesirine with rituximab after stereotactic radiosurgery in CNS lymphomas.

December 8, 2025Blood

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

View Full Paper

Ask AI

Bookmark

Authors

NENarendranath EpperlaUniversity of Utah ABAllison M. BockUniversity of Utah BHBoyu HuThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Phase I trial evaluates safety and efficacy of rituximab and loncastuximab after stereotactic radiosurgery in CNS lymphomas, suggesting improved clinical outcomes.

Key Points

To investigate the safety and feasibility of combining loncastuximab tesirine with rituximab after stereotactic radiosurgery in CNS lymphomas.
Single-arm, open-label, nonrandomized phase 1 study involving adult patients with confirmed CNS lymphomas.
Patients receive stereotactic radiosurgery followed by loncastuximab and rituximab within 14 days post-MRI.
Dose escalation design is utilized to determine maximum tolerated dose and recommended dose for expansion.
The primary endpoint is determining the maximum tolerated dose of the combination treatment.
Secondary endpoints include overall response rate and complete response rate.
As of July 14, 2025, two patients have been enrolled and the study is ongoing.

Cite This Study

Epperla et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e33e https://doi.org/10.1182/blood-2025-8241

View Full Paper

Ask AI

Bookmark

Implication

Phase I trial evaluates safety and efficacy of rituximab and loncastuximab after stereotactic radiosurgery in CNS lymphomas, suggesting improved clinical outcomes.

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Discussion

Member takes

Implication

Key Points

Cite This Study

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider